Summary
For Year 2026-27, Accretion Pharmaceuticals reports the following shareholding: Total Promoters at 73.52%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 26.48%. This breakdown provides a quick snapshot of ownership distribution for Accretion Pharmaceuticals in 2026-27.
Accretion Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Accretion Pharmaceuticals stands at 73.52% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Accretion Pharmaceuticals is 0% and 0% respectively.
The retail shareholding of the Accretion Pharmaceuticals is 26.48%.
Changes in shareholding patterns of Accretion Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Accretion Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Accretion Pharmaceuticals Associated Pages
- Accretion Pharmaceuticals Share Price
- Accretion Pharmaceuticals Share Price chart
- Accretion Pharmaceuticals Fundamental Analysis
- Accretion Pharmaceuticals Technical Analysis
- Accretion Pharmaceuticals Peer Comparison
- Accretion Pharmaceuticals Share Price History
- Accretion Pharmaceuticals Board of Directors
